chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Slightly lightheaded; Slight ringing in my ears; Resting heart rate began to increase; Facial/neck flushing; Became hot; This is a spontaneous report from a contactable nurse, the patient. A 40-year-old non-pregnant female patient received first single dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6200), via an unspecified route of administration on the left arm on 17Mar2021 at 14:15 (at the age of 40-year-old) for COVID-19 immunisation. Concomitant medications (within 2 weeks of vaccination) included vitamin E, hydrolyzed collagen, vitamin C, biotin. She has no known allergies to any medications, food, or other products. She did not receive any other vaccines within 4 weeks prior to the covid-19 vaccine and was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, she had not tested positive for COVID-19. On 17Mar2021 (within 2-3 minutes after the vaccination), she became slightly lightheaded with a slight ringing in her ears; Her resting heart rate began to increase from 70 beats per minute up to 131 beats per minute with facial/neck flushing and she also became hot. The symptoms resolved within the next 2-3 minutes. It was also confirmed that she was 5 hours out from receiving the vaccine without further issue. No therapeutic measures were taken to treat these events. The clinical outcome for the events became hot, facial/neck flushing, resting heart rate began to increase, slightly lightheaded, slight ringing in her ears was recovered on the same day (17Mar2021). No follow-up attempts are needed. No further information is expected.
Pt presented to the hospital with SOB, fever, and lightheadedness. Started with dexamethasone, and augmentin for strep throat. Was given supp oxygen
Nausea, Headache, stomach upset, pale, fainting for 30 second.
Significant coughing post-vaccine. Found unresponsive at home in hot tub 2 days post-vaccine (03/07/2021). Resuscitation efforts were made during EMS ride to helipad, but death was pronounced at the helipad prior to flight at 1850 hrs.
I had a exposure to COVID event and began to feel unwell on 01/06/2022, was tested and confirmed with COVID 01/09/2022. Some of the effects was extreme fatigue and oxygen issues was prescribed Prednisone  for five days, and fluids and a Liquid IV, that dissolves in water. Two weeks in bed, no strength the first week.
pt recv vax & devel an acute debilitating arthralgia in OCT95 approx 3wk post vax;6OCT95 pt devel swollen lymph nodes on both sides of neck & was seen in ER;monospot test 6OCT95 was negative;7OCT95 devel a fever of 100 & knees bilat s
Patient has a raised red bump on her right deltoid about the size of a normal plantar wart.  Area around the bump did not appear to be infected.  Patient said yesterday was the first time the patient noticed any signs. Patient said the bump did not hurt, was not hot, and did not irritate her in any way.
On Thursday around noon, pt. had a headache, chest pains, numbness in left arm, the ER checked his heart rate and it was 215, they did blood work which came back normal & took more blood 4 hours later to check for heart damage, They admitted him to the hospital and did an EKG the next day that did not show any negative results (you'd have to get that from the hospital) They completed an  Angiogram and found no blockage.  Today, April 17th, I believe they did a cat scan of his lungs to check for blood clots and I am not sure of the results.
Patient awoke around 6-7 am with a blotchy, red, rash on her face. Non- itchy. Received Rabies immune globulin and vaccine about 15 hour prior. No local or systemic reactions.
I had the second dose .shingrix vaccine on October 21st. Within 12 hours, i felt ill, flu- like symptoms which lasted app 24 hrs. On December 1st, I experienced R cranial nerve pain and within 36 hrs I presented to an acute care hospital ER with a dx of r/o stroke - having symptoms of numbness around mouth, slurred speech, drooping R side mouth and severe drooping R eye, I am an otherwise healthy, active senior citizen with no hx of Bell's Palsy or other related dx.
bruising, some edema, warm to touch;no nausea or vomiting, or pain;c/o itching in inj site only;reports area only uncomfortable;
At 11:32 AM, patient was seated in a chair and was talking, no complaints voiced.  At 11:35 AM, after all 4 vaccinations were given, patient dropped his chin to hischest and took two snoring respirations.  Upon asking the patient if he was okay X2, patient picked head up and stated yes then stated that he felt warm.  11:35 AM, patient VS taken and were WNL (65-20 133/81  and O2 sat on RA = 97%. Given 8 oz apple juice and encouraged to take deep breaths.   11:45 AM, patient stated he felt "back to normal, like when I walked in".  Ate 2 cups of applesauce without difficulty or assistance.    11:58 AM, patient VS taken and were WNL (68-16 124/68  and O2 sat on RA = 97%. Patient stated that he felt "fine now".  Abl e to stand and walk independently. skin w/d with color WNL. Speech clear and apprpriate.  MAE independently and uppn command.  12:00 PM, patient stated he was "okay to go now".and left clinic independently.
Pain in left arm, collarbone; Pain in left arm, collarbone; Swollen lymph nodes; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (Pain in left arm, collarbone), PAIN IN EXTREMITY (Pain in left arm, collarbone) and LYMPHADENOPATHY (Swollen lymph nodes) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BONE PAIN (Pain in left arm, collarbone), PAIN IN EXTREMITY (Pain in left arm, collarbone) and LYMPHADENOPATHY (Swollen lymph nodes). At the time of the report, BONE PAIN (Pain in left arm, collarbone) and LYMPHADENOPATHY (Swollen lymph nodes) outcome was unknown and PAIN IN EXTREMITY (Pain in left arm, collarbone) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.   No treatment information was provided.
little side effects; This spontaneous case was reported by a patient and describes the occurrence of IMMUNISATION REACTION (little side effects) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (little side effects). At the time of the report, IMMUNISATION REACTION (little side effects) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant medication was reported.  Patient had just finished a documentary about Pfizer - so Patient was not really feeling "close" or good about them as a pharmaceutical brand. Patient had Moderna and had little side effects - much different than patient friends who had Pfizer.  No treatment information was reported.   Reporter did not allow further contact
Moderna Bivalent given unnecessarily.  Patient had already been given this dose on 11/8/2022.
Vaccine administered after temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after temperature excursion) and EXPIRED PRODUCT ADMINISTERED (Vaccine administered after temperature excursion) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after temperature excursion) and EXPIRED PRODUCT ADMINISTERED (Vaccine administered after temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after temperature excursion) and EXPIRED PRODUCT ADMINISTERED (Vaccine administered after temperature excursion) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   The healthcare facility had an power outage on 01 April 2021. This dropped the temperature of the vials stored in freezer and refrigerator to -  Frozen vaccine 47 minutes -13.79 degree celsius Refrigerator 59 minutes 12 degree Celsius  Treatment information was not provided.  Concomitant medications were not reported.
Site of injection was tender.  Could feel lump when palpating arm.  Lump has grown, has fever, and severe tenderness.
headache; This is a spontaneous report received from contactable reporter(s) (Other HCP) for a Pfizer sponsored program (1423231).  A 40 year-old female patient received bnt162b2 (BNT162B2), administration date 02Mar2022 (Batch/Lot number: unknown) at the age of 40 years as dose number unknown, single for covid-19 immunisation; palbociclib (IBRANCE), since 24Feb2021 (Batch/Lot number: unknown) at 100 mg. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: HEADACHE (non-serious) with onset 02Mar2022, outcome "unknown", described as "headache".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
5 MINS AFTER RECEIVING VACCINE, FELT HOT, CLAMMY, AND NAUSEA. ASSISTED TO FLOOR TO RAISE FEET BY STAFF. BROUGHT BACK VIA WHEELCHAIR, S/S RESOLVED ONCE ARRIVING. EXCORTED TO EXIT WITHOUT ISSUES AT 1045. 1033 INITIAL BP 128/62 HR 56 RR 18 SATS 98% RA 1041 SITTING BP 133/80 HR 63 RR 18 SATS 98% RA 1043 STANDING BP 124/71 HR 77 RR 18 SATS 97% RA
This case was reported by non-health professional via sales rep and described the occurrence of pain in arm in a 69-year-old female patient who received SHINGRIX. On 20th April 2018, the patient received the 1st dose of SHINGRIX .5 ml. In April 2018, less than a week after receiving SHINGRIX, the patient experienced extremities hot feeling of, swelling arm, induration and erythema of extremities. On 20th April 2018, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm, extremities hot feeling of, swelling arm, induration and erythema of extremities were not recovered/not resolved. It was unknown if reporter considered the pain in arm, extremities hot feeling of, swelling arm, induration and erythema of extremities to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX vaccine in the deltoid muscle of left arm. The patient stated that the arm was hot swollen hard and painful. She had experienced pain upon injection but called office 5 days later on 25th April 2018 to say her arm was still red swollen and painful. The doctor suggested to take whatever she normally took for pain (i.e. NSAID). The patient replied that she did not take anything for pain. The patient did not seek medical attention just called office to alert them that what they told her might happen did but she did make a point to emphasize the pain. The patient's arm pain had not gotten any better since date of injection.
Woke up in the morning uncontrollably shaking for 30 minutes. Pain from injection site in left shoulder to whole left pectoral muscle of my chest and armpit. Chills and body aches. Congestion and productive cough. Eyes extremely sensitive to light and movement. Sore and swollen throat.
3-27-21 redness, hard, itching to injection site.spoke to pharmacist and was told to take benadryl reports not taking any as symptoms resolved within 24hrs
Information has been received from a doctor's nurse concerning a 4 year old male patient who in 2005 was vaccinated with the first dose of VARIVAX (Merck). Then the patient was given VARIVAX (Merck), MMR II (MSD) (rHA, lot # 659705/0356X), DTAP (lot # C2999AA, manufacturer unknown) and poliovirus vaccine inactivated (VERO) (+) tetanus toxoid (lot # A1229, manufacturer unknown) concomitantly. The VARIVAX (Merck) and DTAP were administered in the patient's left thigh and the MMR II and poliovirus vaccine inactivated (VERO) (+) tetanus toxoid were administered in his right thigh. On 06-JUN-2009, the parents reported that there was "rapidly spreading erythema" on his left thigh. "Eventually it got to 18 centimeters by 9 centimeters." The nurse reported that it was an "Erythematous macular rash, which was warm and slightly indurated, and it was diagnosed as cellulitis secondary to vaccination." The patient was given "DURICES" (Manufacturer unknown) 500mg and BACTROBAN. It's also reported from a field employee that this is the 6th VARIVAX (Merck) AE from this office about for cellulitis. The nurse told that this started happening when they started getting single vials of VARIVAX (Merck) instead of the 10 packs. The a field employee said that his records show that they have not been from the same lot number. Follow up information has been received from the doctor's nurse reported that the 4 year old male patient with no pre-existing allergies, birth defects, or medical conditions who on 04-JUN-2009 was vaccinated with the second dose of VARIVAX (Merck) on the left thigh and the second dose of MMR II on the right thigh. Two days after vaccines, the patient's leg (left thigh) was warm, swollen and had 18 cm x 9.5 cm cellulitis which started on 04-JUN-2009. Subsequently the patient was recovered on approximately 16-JUN-2009. The patient was "well" at the time of vaccination. Additional information is not expected.
Fever to 103F. Profound headache, chills, rigors and body aches.  Lasted for total of 5 days; fever resolved on day 6. Symptom free (other than low grade fever ) on day 5.
Pt became very ill with fever that began less than 24 hrs after vaccination. The illness was severe and lasted three to four days. The second day was the most severe.
Feeling very tired and achy all day, around 2:00 PM noticed a low grade fever.
Shingles. After receiving the vaccine on March 31 I experience being tired which I expected. Soreness at injection site for a couple days. Then felt fine until April 8 when I woke to a little tightness in my right lower back. The pain progress as shingles does and on the afternoon of the 9th i went to the emergency room and learned I had shingles. Blisters developed while at the hospital. I took the 2nd shot on schedule with very miner after effects of shingles. I hope that people will consider the shingles vaccine or allow for people under 50 to get it. A 35 year old friend had same issue but will not fill out a report  :-/
This spontaneous report was received from a nurse refers to a 27 year old female patient with purpura and blood dyscrasia for which she did not take medication. On an unknown date the patient was vaccinated with the first dose of GARDASIL injection 120 Y, route, dosage, lot number and expiration date were not reported. Concomitant therapy was not reported. The reporter informed that on an unknown date after vaccination, the patient discovered she was pregnant, she received her second dose of GARDASIL after she delivered her infant on an unspecified date, the pregnancy outcome was live birth, fetal outcome was unknown, but she could not get her third dose because her insurance ran out now that she has insurance, she would like to receive her third dose of GARDASIL, the patient was not reporting or demonstrating any adverse effects. Additional information has been requested.
Patient admitted to hospital and received COVID 19 bivalent vaccine and influenza vaccine on 10/20/22. Patient identified that they had previously received these vaccines ~1 month ago at outside location. Doses on 10/20 should not have been administered. As the previous dose was administered outside of our system, documentation of these vaccines was not available in patient's chart at the time.
Shivering, felt tired, sore arm and redness below injection site for several days.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 10Mar2021 as dose 1, single (Lot number: EN6208), on 05Oct2021 as dose 2, single (Lot number: 301458A) and on 17Feb2022 as dose 3 (booster), single (Lot number: FL9266) for covid-19 immunisation. The patient's relevant medical history included: "Diabetes mellitus" (unspecified if ongoing). Concomitant medication(s) included: SYNTHROID; ZYRTEC [CETIRIZINE HYDROCHLORIDE]; DELSYM. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.   Clinical information: Treatment drug included Paxlovid from 20May2022 to 26May2022. Other medication in 2weeks included the concomitant drugs mentioned above.
STEMI heart attack, clot in right coronary artery, 3 days in hospital 4/10/21 to 4/13/21
Patient brought into Covid Observation area 20 minutes after receiving Moderna booster. Reports tingling sensation to lips and tongue and tight feeling in throat.  Patient denies any difficulty breathing. No swelling to face, lips, and tongue noted.  Able to swallow to saliva and water without difficulty. No wheezing noted. Patient alert and oriented x 4, speaking in complete sentences. Denies experiencing any of these symptoms after 1st two doses of Moderna. Accompanied by his wife.  10:29 am- VS- Temp 97.7, BP 155/90, HR 53, RR 18, 02 SATs 95%RA  10:32 am- Call placed to on call ED physician, informed of patient symptoms above. Verbal order given for Benadryl 25 mg orally x 1 now. Per Dr., continue to monitor patient for 30 minutes, if symptoms improved, ok to discharge home. If symptoms worsen, patient to go to ED. Verbal order repeated and confirmed.  10:36 am- Benadryl 25 mg orally given as ordered.   10:45 am- VS- BP 148/79, HR 54, RR 20, 02 SATs 95%. Patient reports tingling sensation to lips and tongue remain unchanged, throat tightness lessening.  10:57 am- VS- BP 162/78, HR 55, RR 20, 02 SATs 95% RA Patient reports tightness in throat improving and throat/neck area feels numb on both sides, but he is able to feel touch. Denies any difficulty breathing or swallowing. Reports tingling to lips and tongue improving. Denies any chest pain or weakness or numbness to face or extremities.  11:07 am- VS- Temp 97.6, BP 153/80, HR 55, RR 18, 02 SATs 96%RA. Patient symptoms remain unchanged and no new symptoms reported.   11:22 am- Patient reports improving tingling sensation to lips, tongue and lessening tight feeling in throat. Denies any new or worsening symptoms. Denies any difficulty breathing. Speaking in complete sentences with wife who is at bedside. VS: BP 140/72, HR 68, RR 20, 02 SATs 97%.  11:36 am- Patient reports improved tingling sensation to lips and tongue. Denies any tightness to throat. Also denies any throat swelling or itching. Reports numb feeling to both sides of neck, unchanged, not worse. Denies any difficulty breathing or swallowing.   11:39am- Patient discharged home in stable condition, accompanied by his wife who will drive him home. Advised to call 911 or go to nearest ED if symptoms return or worsen. Patient and wife verbalized understanding.
This spontaneous report as received from a Licensed Practical Nurse refers to a patient of unknown age and gender. On an unspecified dates the patient was vaccinated with 2 doses of VARIVAX (Merck), (doses, route, lot numbers and expiration dates not reported). On an unknown date the patient had titers drawn that had shown failure to seroconvert (negative titers). At the time of the report the outcome of failure to seroconvert (negative titers) was unknown. Additional information has been requested.
Mother giving child bath at night and notice site was red and swollen, child had complained of pain earlier but mother states all of her children complain of injection pain.  This AM size of redness as increased, swelling decreased.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Nov-2021 at 3:08 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 03-Nov-2021 at 3:08 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 66.87   Concomitant products were not provided.  On 03-Nov-2021 Excursion time was 10:00 A.M., temperature was 35 degrees Fahrenheit, total doses given for the day was 117, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 05-Oct-2021, vial was moved to clinic on 03-Nov-2021. 6 vials were sent to clinic. Vaccine BUD date was 05-Nov-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Information has been received from a licensed practical nurse concerning a 59 year old male patient who on 05-OCT-2009 was vaccinated subcutaneously with a dose of PNEUMOVAX 23 (lot# 662841/0626Y) into his left arm. Concomitant therapy included "influenza" (manufacturer, Sanofi, lot# U3195AP) which was administered intramuscularly into his right deltoid on 05-OCT-2009. Subsequently (also reported on 07-SEP-2009) the patient experienced left arm red and warm area. The patient told doctor that he did not have cold pack and had taken BENADRYL. The patient did not seek medical attention. On an unspecified date, the patient had recovered. Follow-up information has been received from the licensed practical nurse who stated that the AE onset date was 07-OCT-2009 and not on 07-SEP-2009 as previously reported. Additional information is not expected.